Health
Diets high in sugary and artificially sweetened beverages were associated with a 9% increase in the risk of early death...
Digital Desk: A recent study conducted by Harvard
Bengaluru: Zydus Cadila’s three-dose vaccine for children above 12 years has been approved by India’s drug regulator on Friday. The company plans to manufacture 100 million to 120 million doses of ZyCov-D annually and has already started to store up the vaccine.
The vaccine is said to have an efficacy rate of 66.6 percent against symptomatic patients and 100% against moderate or severe disease according to its phase 3 trial data.
ZyCoV-D is a first-of-its-kind DNA vaccine that produces the spike protein of the SARS-CoV-2 to elicit an immune response and the vaccine has to be jabbed using a needle-free injector.
The production of ZyCov-D was started on 23 April 2021.
The vaccine is developed by Indian pharmaceutical company Cadila Healthcare with support from the Biotechnology Industry Research Assistance Council.
Leave A Comment